A recent study conducted by the Harvard Medical School reveals Cyclin D1 to be a potential anti-inflammatory target.

Cyclin D1 is an important cell cycle-regulatory molecule and an established therapeutic target for cancer. Cyclin D1 has been observed to be strongly up-regulated at sites of inflammation, so the scientists selectively silenced Cyclin D1 in leukocytes in vivo. Their approach included targeted stabilised nanoparticles (tsNPs) that were loaded with Cyclin D1-small interfering RNA (siRNA) and antibodies directed against integrin-β7 that were used to detect the specific leukocyte subsets involved in gut inflammation. Integrin-β7-tsNP-delivered Cyclin D1-siRNA successfully silenced Cyclin D1 in leukocytes and could cure experimentally induced colitis in mice by suppressing leukocyte proliferation and T helper cell 1 cytokine expression. The application of similar methodologic approaches with siRNA may be effective in other experimental settings as well.

Related antibodies on antibodies-online.com:

Cyclin D1

Leukocyte antigen CD97

Leukocytes (peripheral blood)

Integrin-β7

Antibodies for the research area cell cycle: »Show antibodies

Antibodies for the research area inflammation: »Show antibodies

Antibodies for the research area oncologie: »Show antibodies